rilimogene galvacirepvec/rilimogene glafolivec
AXP000178.1 · Cancer vaccine
- Platform
- poxvirus prime-boost (vaccinia prime, fowlpox boost)
- Targets
- KLK3
- Originator
- National Cancer Institute; Therion Biologics
- Sponsor
- Bavarian Nordic
Names
| Name | Type | Source |
|---|---|---|
| rilimogene galvacirepvec/rilimogene glafolivec | preferred name | curator |
| rilimogene galvacirepvec | INN | ncit |
| rilimogene glafolivec | INN | ncit |
| PROSTVAC | code | ncit |
| PROSTVAC-VF | code | ncit |
| PROSTVAC-VF/TRICOM | code | ncit |
| PSA-TRICOM | synonym | curator |
| rF-PSA-TRICOM | synonym | ncit |
| rV-PSA-TRICOM | synonym | ncit |
Virus
- Role
- Vaccine vector
- Family
- Poxviridae
- Virus
- vaccinia virus (NCBI Taxonomy 10245)
- Strain
- PROSTVAC-V (vaccinia) prime; PROSTVAC-F (fowlpox) boost
- Replication
- replicating
- Modifications
- PSA and TRICOM cassettes inserted; replication-competent vaccinia prime, non-replicating fowlpox boost
- Transgenes
- KLK3, CD80, ICAM1, CD58
- Route
- subcutaneous
- Source
- evidence
Cross-references
- NCI Thesaurus
- C132990
Approvals
No regulatory approval recorded.
Clinical trials (21)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT04020094 | Perioperative Atezolizumab With MVA-BN-Brachyury and PROSTVAC For Intermediate-Risk And High-Risk Localized Prostate Cancer | Withdrawn | Phase 2 | 2019-11-20 | 2021-04-09 | 0 | Prostate Adenocarcinoma |
| NCT03532217 | Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer | Completed | Phase 1 | 2018-09-14 | 2022-04-01 | 19 | Metastatic Hormone-Sensitive Prostate Cancer |
| NCT03315871 | Combination Immunotherapy in Biochemically Recurrent Prostate Cancer | Completed | Phase 2 | 2018-03-20 | 2024-06-04 | 40 | Prostate Cancer |
| NCT02933255 | PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer | Completed | Phase 1/2 | 2017-04-18 | 2023-06-20 | 24 | Prostate Cancer |
| NCT02506114 | Neoadjuvant PROSTVAC-VF With or Without Ipilimumab for Prostate Cancer | Terminated | Phase 2 | 2016-10-06 | 2020-04-22 | 15 | Prostatic Neoplasms |
| NCT02772562 | Adjuvant PROSTVAC-V/F in Subjects at High Risk for Relapse After Radical Prostatectomy | Terminated | Phase 2 | 2016-07-18 | 2024-04-29 | 33 | Prostatic Neoplasms |
| NCT02649855 | Docetaxel and PROSTVAC for Metastatic Castration-Sensitive Prostate Cancer | Completed | Phase 2 | 2016-01-19 | 2022-07-01 | 74 | Neoplasms, Prostatic; Prostate Cancer; Prostate Neoplasms |
| NCT02649439 | Prostvac in Patients With Biochemically Recurrent Prostate Cancer | Completed | Phase 2 | 2015-12-22 | 2019-03-28 | 97 | Prostate Cancer |
| NCT02326805 | PROSTVAC (PSA-TRICOM) in Preventing Disease Progression in Patients With Localized Prostate Cancer Undergoing Active Surveillance | Completed | Phase 2 | 2015-06-03 | 2018-11-30 | 154 | Stage I Prostate Adenocarcinoma AJCC v7; Stage II Prostate Adenocarcinoma AJCC v7 |
| NCT02153918 | Vaccine Plus Booster Shots in Men With Prostate Cancer Undergoing Treatment With Radical Prostatectomy | Completed | Phase 2 | 2014-05-31 | 2017-07-28 | 27 | Neoplasms, Prostate; Prostate Cancer; Prostatic Neoplasms |
| NCT01867333 | Enzalutamide With or Without Vaccine Therapy for Advanced Prostate Cancer | Completed | Phase 2 | 2013-08-12 | 2022-09-28 | 57 | Prostate Cancer |
| NCT01875250 | Enzalutamide in Combination With PSA-TRICOM in Patients With Non-Metastatic Castration Sensitive Prostate Cancer | Completed | Phase 2 | 2013-07-22 | 2019-09-01 | 38 | Prostate Cancer |
| NCT01322490 | A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer | Completed | Phase 3 | 2011-11-28 | 2017-09-25 | 1297 | Prostate Cancer Metastatic |
| NCT01145508 | Docetaxel and Prednisone With or Without Vaccine Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | Terminated | Phase 2 | 2010-08 | 2012-10 | 10 | Hormone-Resistant Prostate Cancer; Prostate Adenocarcinoma; Recurrent Prostate Carcinoma; Stage IV Prostate Cancer |
| NCT00450463 | Vaccine Therapy With PROSTVAC/TRICOM and Flutamide Versus Flutamide Alone to Treat Prostate Cancer | Completed | Phase 2 | 2007-02-23 | 2017-04-27 | 64 | Prostate Cancer |
| NCT00108732 | A Phase II Study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM With GM-CSF in Patients With PSA Progression After Local Therapy for Prostate Cancer | Completed | Phase 2 | 2006-02 | 2010-10 | 50 | Recurrent Prostate Carcinoma; Stage I Prostate Cancer; Stage IIA Prostate Cancer; Stage IIB Prostate Cancer; Stage III Prostate Cancer |
| NCT00113984 | Vaccine and Antibody Treatment of Prostate Cancer | Completed | Phase 1 | 2005-06-08 | 2008-02-01 | 30 | Prostatic Neoplasms |
| NCT00096551 | A Phase I Feasibility Study of an Intraprostatic PSA-Based Vaccine in Men With Prostate Cancer With Local Failure Following Radiotherapy or Cryotherapy or Clinical Progression on Androgen Deprivation Therapy in the Absence of Local Definitive Therapy | Completed | Phase 1 | 2004-11-01 | 2009-12-11 | 21 | Prostatic Neoplasms |
| NCT00078585 | PROSTVAC®-VF/TRICOM™ Vaccine for the Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy | Completed | Phase 2 | 2003-11 | 2006-01-04 | 120 | Prostate Cancer |
| NCT00060528 | Sequential Vaccinations in Prostate Cancer Patients | Completed | Phase 1/2 | 2003-05-22 | 2006-03-07 | 32 | Prostatic Neoplasms |
| NCT00001382 | A Phase I Study of Recombinant Vaccinia Virus That Expresses Prostate Specific Antigen in Adult Patients With Adenocarcinoma of the Prostate | Completed | Phase 1 | 1994-03 | 75 | Prostatic Neoplasms |
Unconfirmed matches (1)
Trials that mention one of the names in a weaker way (a code only in the title, a short or ambiguous name). Not counted above.
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions | Matched by |
|---|---|---|---|---|---|---|---|---|
| NCT00450619 | 153Sm-EDTMP With or Without a PSA/TRICOM Vaccine To Treat Men With Androgen-Insensitive Prostate Cancer | Completed | Phase 2 | 2007-02 | 2012-11 | 44 | Prostate Cancer | name in title: PSA-TRICOM |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 42671172 | Long-Term Oncologic Outcomes of Neoadjuvant Tumor-Directed Immunotherapy (PROSTVAC) Before Radical Prostatectomy for Localized Prostate Cancer: A Secondary Analysis of a Neoadjuvant Trial. | The Prostate | 2026 | name in title: PROSTVAC |
| PMID 40550568 | Programmed death-1 inhibition increases vaccine-induced T-cell infiltration in patients with prostate cancer. | Journal for immunotherapy of cancer | 2025 | cited by trial NCT02933255 |
| PMID 37858437 | Quantitative Analysis of Serial Positron Emission Tomography Imaging in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide. | European urology oncology | 2024 | name in abstract: PROSTVAC |
| PMID 36517408 | A Phase 2, Double-blind, Randomized Controlled Trial of PROSTVAC in Prostate Cancer Patients on Active Surveillance. | European urology focus | 2023 | name in title: PROSTVAC |
| PMID 37134294 | Flutamide With or Without PROSTVAC in Non-metastatic Castration Resistant (M0) Prostate Cancer. | The oncologist | 2023 | cited by trial NCT00450463 |
| PMID 33664086 | Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancer. | Journal for immunotherapy of cancer | 2021 | cited by trial NCT01875250 |
| PMID 32269146 | Neoadjuvant PROSTVAC prior to radical prostatectomy enhances T-cell infiltration into the tumor immune microenvironment in men with prostate cancer. | Journal for immunotherapy of cancer | 2020 | cited by trial NCT02153918 |
| PMID 30817251 | Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2019 | cited by trial NCT01322490 |
| PMID 30197041 | A Randomized, Double-blind, Phase II Trial of PSA-TRICOM (PROSTVAC) in Patients with Localized Prostate Cancer: The Immunotherapy to Prevent Progression on Active Surveillance Study. | European urology focus | 2018 | cited by trial NCT02326805 |
| PMID 30563577 | Myocarditis in a patient treated with Nivolumab and PROSTVAC: a case report. | Journal for immunotherapy of cancer | 2018 | name in title: PROSTVAC |
| PMID 27646950 | Revised Overall Survival Analysis of a Phase II, Randomized, Double-Blind, Controlled Study of PROSTVAC in Men With Metastatic Castration-Resistant Prostate Cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2017 | cited by trial NCT00078585 |
| PMID 27486817 | Samarium-153-EDTMP (Quadramet®) with or without vaccine in metastatic castration-resistant prostate cancer: A randomized Phase 2 trial. | Oncotarget | 2016 | name in abstract: PSA-TRICOM |
| PMID 25533418 | A national multicenter phase 2 study of prostate-specific antigen (PSA) pox virus vaccine with sequential androgen ablation therapy in patients with PSA progression: ECOG 9802. | European urology | 2015 | name in abstract: PROSTVAC |
| PMID 26111351 | Randomized phase II trial of docetaxel with or without PSA-TRICOM vaccine in patients with castrate-resistant metastatic prostate cancer: A trial of the ECOG-ACRIN cancer research group (E1809). | Human vaccines & immunotherapeutics | 2015 | name in title: PSA-TRICOM |
| PMID 24474335 | Identification by digital immunohistochemistry of intratumoral changes of immune infiltrates after vaccine in the absence of modifications of PBMC immune cell subsets. | International journal of cancer | 2014 | name in abstract: rV-PSA-TRICOM |
| PMID 24514956 | A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates. | Cancer immunology, immunotherapy : CII | 2014 | name in abstract: PROSTVAC |
| PMID 24733910 | Humoral response to a viral glycan correlates with survival on PROSTVAC-VF. | Proceedings of the National Academy of Sciences of the United States of America | 2014 | name in title: PROSTVAC-VF |
| PMID 24778277 | Immune impact induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer. | Cancer immunology research | 2014 | name in title: PSA-TRICOM |
| PMID 23836412 | Phase I study of intraprostatic vaccine administration in men with locally recurrent or progressive prostate cancer. | Cancer immunology, immunotherapy : CII | 2013 | name in abstract: rV-PSA-TRICOM |
| PMID 22326924 | Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. | The Lancet. Oncology | 2012 | name in abstract: PSA-TRICOM |
| PMID 20976449 | Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccination. | Cancer immunology, immunotherapy : CII | 2011 | name in abstract: PSA-TRICOM |
| PMID 20100959 | Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2010 | cited by trial NCT00078585 |
| PMID 17707059 | cited by trial NCT00060528 | |||
| PMID 22932804 | cited by trial NCT00060528 |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 38277189 | Nonsurgical Interventions to Prevent Disease Progression in Prostate Cancer Patients on Active Surveillance: A Systematic Review and Meta-analysis. | European urology oncology | 2024 | name in abstract: PROSTVAC |
| PMID 36835981 | Immunotherapy for Prostate Cancer: A Current Systematic Review and Patient Centric Perspectives. | Journal of clinical medicine | 2023 | name in abstract: PROSTVAC |
| PMID 33866131 | Drug and molecular radiotherapy combinations for metastatic castration resistant prostate cancer. | Nuclear medicine and biology | 2021 | name in abstract: PROSTVAC |
| PMID 34729217 | Therapeutic metastatic prostate cancer vaccines: lessons learnt from urologic oncology. | Central European journal of urology | 2021 | name in abstract: PROSTVAC |
| PMID 31350066 | Re: Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-resistant Prostate Cancer. | European urology | 2020 | name in title: PROSTVAC |
| PMID 32057540 | Deep androgen receptor suppression in prostate cancer exploits sexually dimorphic renal expression for systemic glucocorticoid exposure. | Annals of oncology : official journal of the European Society for Medical Oncology | 2020 | name in abstract: PROSTVAC |
| PMID 30913454 | Emerging therapeutic targets for patients with advanced prostate cancer. | Cancer treatment reviews | 2019 | name in abstract: PROSTVAC-VF |
| PMID 31482315 | Immunotherapy in Metastatic Castration-Resistant Prostate Cancer: Past and Future Strategies for Optimization. | Current urology reports | 2019 | name in abstract: PROSTVAC |
| PMID 29231062 | Promising immunotherapy for prostate cancer. | Expert opinion on biological therapy | 2018 | name in abstract: PSA-TRICOM |
| PMID 29709495 | Morphological changes induced by intraprostatic PSA-based vaccine in prostate cancer biopsies (phase I clinical trial). | Human pathology | 2018 | name in abstract: PSA-TRICOM |
| PMID 28376158 | Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment. | Journal of the National Cancer Institute | 2017 | name in abstract: PSA-TRICOM |
| PMID 28771597 | Development and validation of a Luminex assay for detection of a predictive biomarker for PROSTVAC-VF therapy. | PloS one | 2017 | name in title: PROSTVAC-VF |
| PMID 29146441 | Combining immunotherapies for the treatment of prostate cancer. | Urologic oncology | 2017 | name in abstract: PSA-TRICOM |
| PMID 29183736 | Immunotherapy in the Elderly. | European urology focus | 2017 | name in abstract: PROSTVAC |
| PMID 26977847 | The evolving role of immunotherapy in prostate cancer. | Current opinion in oncology | 2016 | name in abstract: PROSTVAC |
| PMID 27076165 | Cancer Vaccines: A Brief Overview. | Methods in molecular biology (Clifton, N.J.) | 2016 | name in abstract: PROSTVAC-VF |
| PMID 27485137 | Analyses of Pretherapy Peripheral Immunoscore and Response to Vaccine Therapy. | Cancer immunology research | 2016 | name in abstract: PROSTVAC |
| PMID 27749327 | Immune Therapy for Prostate Cancer. | Cancer journal (Sudbury, Mass.) | 2016 | name in abstract: PSA-TRICOM |
| PMID 25747158 | Cancer vaccines: can they improve survival? | Cancer biotherapy & radiopharmaceuticals | 2015 | name in abstract: PROSTVAC-VF |
| PMID 25894495 | Immunotherapy in prostate cancer. | Current urology reports | 2015 | name in abstract: PSA-TRICOM |
| PMID 26022286 | [New therapies in metastatic castration resistant prostate cancer]. | Bulletin du cancer | 2015 | name in abstract: PROSTVAC-VF |
| PMID 26060311 | Correction for Campbell et al., Humoral response to a viral glycan correlates with survival on PROSTVAC-VF. | Proceedings of the National Academy of Sciences of the United States of America | 2015 | name in title: PROSTVAC-VF |
| PMID 26161414 | Beyond the Immune Suppression: The Immunotherapy in Prostate Cancer. | BioMed research international | 2015 | name in abstract: PROSTVAC-VF |
| PMID 26235179 | Development of PROSTVAC immunotherapy in prostate cancer. | Future oncology (London, England) | 2015 | name in title: PROSTVAC |
| PMID 26338967 | ABO blood type correlates with survival on prostate cancer vaccine therapy. | Oncotarget | 2015 | name in abstract: PROSTVAC-VF |
| PMID 24402184 | Beyond sipuleucel-T: immune approaches to treating prostate cancer. | Current treatment options in oncology | 2014 | name in abstract: PROSTVAC-VF |
| PMID 24435055 | Immunotherapy and therapeutic vaccines in prostate cancer: an update on current strategies and clinical implications. | Asian journal of andrology | 2014 | name in abstract: PSA-TRICOM |
| PMID 24477411 | Immunotherapy for prostate cancer: recent developments and future challenges. | Cancer metastasis reviews | 2014 | name in abstract: PROSTVAC-VF |
| PMID 24571737 | Targeting kallikrein-related peptidases in prostate cancer. | Expert opinion on therapeutic targets | 2014 | name in abstract: PROSTVAC |
| PMID 24620782 | Sipuleucel-T and immunotherapy in the treatment of prostate cancer. | Expert opinion on biological therapy | 2014 | name in abstract: PROSTVAC |
| PMID 24762070 | PROSTVAC® targeted immunotherapy candidate for prostate cancer. | Immunotherapy | 2014 | name in title: PROSTVAC |
| PMID 24775724 | Practical guide to immunotherapy in castration resistant prostate cancer: the use of sipuleucel-T immunotherapy. | The Canadian journal of urology | 2014 | name in abstract: PSA-TRICOM |
| PMID 24858824 | The use of the EVITA algorithm for clinical assessment of novel agents used in prostate cancer, metastatic melanoma, and systemic lupus erythematosus. | European journal of clinical pharmacology | 2014 | name in abstract: PROSTVAC |
| PMID 25097802 | Poxviral-based vaccine elicits immunologic responses in prostate cancer patients. | Oncoimmunology | 2014 | name in abstract: PROSTVAC |
| PMID 25177493 | Therapeutic vaccines as a promising treatment modality against prostate cancer: rationale and recent advances. | Therapeutic advances in vaccines | 2014 | name in abstract: PSA-TRICOM |
| PMID 25259804 | Molecular insights into the development of T cell-based immunotherapy for prostate cancer. | Expert review of clinical immunology | 2014 | name in abstract: PROSTVAC-VF |
| PMID 25328681 | Elucidating immunologic mechanisms of PROSTVAC cancer immunotherapy. | Journal for immunotherapy of cancer | 2014 | name in title: PROSTVAC |
| PMID 25518354 | [Current status and prospects of immunotherapy for castration-resistant prostate cancer]. | Nihon rinsho. Japanese journal of clinical medicine | 2014 | name in abstract: PROSTVAC-VF |
| PMID 23272970 | Castration resistant prostate cancer (CRPC): state of the art, perspectives and new challenges. | Anti-cancer agents in medicinal chemistry | 2013 | name in abstract: PROSTVAC-VF |
| PMID 23337757 | Demystifying immunotherapy in prostate cancer: understanding current and future treatment strategies. | Cancer journal (Sudbury, Mass.) | 2013 | name in abstract: PSA-TRICOM |
| PMID 23362327 | Serum antibodies to blood group A predict survival on PROSTVAC-VF. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2013 | name in title: PROSTVAC-VF |
| PMID 23714490 | Therapeutic vaccines and immunotherapy in castration-resistant prostate cancer: current progress and clinical applications. | American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting | 2013 | name in abstract: PSA-TRICOM |
| PMID 23757912 | [Immunotherapy: a therapeutic revolution against prostate cancer?]. | Revue medicale suisse | 2013 | name in abstract: PROSTVAC-VF |
| PMID 23880851 | Recent progress in pharmaceutical therapies for castration-resistant prostate cancer. | International journal of molecular sciences | 2013 | name in abstract: PROSTVAC |
| PMID 24166056 | [New therapy concepts for castration-resistant prostate cancer: between hormone manipulation, targeted therapy and chemotherapy]. | Der Urologe. Ausg. A | 2013 | name in abstract: PROSTVAC |
| PMID 21748753 | Emerging treatment options for patients with castration-resistant prostate cancer. | The Prostate | 2012 | name in abstract: PROSTVAC |
| PMID 22001436 | Current vaccination strategies for prostate cancer. | European urology | 2012 | name in abstract: PROSTVAC-VF |
| PMID 22209376 | Novel molecular targets for the therapy of castration-resistant prostate cancer. | European urology | 2012 | name in abstract: PROSTVAC-VF/TRICOM |
| PMID 22295041 | Emerging novel therapies for advanced prostate cancer. | Therapeutic advances in urology | 2012 | name in abstract: PROSTVAC-VF |
| PMID 22328018 | Current status of immunological approaches for the treatment of prostate cancer. | Current opinion in urology | 2012 | name in abstract: PROSTVAC-VF |
| PMID 22393799 | Optimizing outcomes of advanced prostate cancer: drug sequencing and novel therapeutic approaches. | Oncology (Williston Park, N.Y.) | 2012 | name in abstract: PROSTVAC-VF |
| PMID 22413824 | Poxviral vectors for cancer immunotherapy. | Expert opinion on biological therapy | 2012 | name in abstract: PROSTVAC-VF |
| PMID 22595052 | Clinical evaluation of TRICOM vector therapeutic cancer vaccines. | Seminars in oncology | 2012 | name in abstract: rF-PSA-TRICOM |
| PMID 22666217 | Emerging targeted therapies for castration-resistant prostate cancer. | Frontiers in endocrinology | 2012 | name in abstract: PROSTVAC-VF |
| PMID 22672122 | New developments in castrate-resistant prostate cancer. | BJU international | 2012 | name in abstract: PROSTVAC |
| PMID 22913261 | Prostate cancer vaccines in clinical trials. | Expert review of vaccines | 2012 | name in abstract: PROSTVAC |
| PMID 22918924 | The evolving role of immunotherapy in prostate cancer. | Annals of oncology : official journal of the European Society for Medical Oncology | 2012 | name in abstract: PROSTVAC-VF |
| PMID 23040162 | Integration of immunotherapy into the management of advanced prostate cancer. | Urologic oncology | 2012 | name in abstract: PROSTVAC |
| PMID 23138168 | New agents in metastatic prostate cancer. | Journal of the National Comprehensive Cancer Network : JNCCN | 2012 | name in abstract: PROSTVAC-VF |
| PMID 23213665 | News studies: combining PROSTVAC with conventional cancer therapy. | Human vaccines & immunotherapeutics | 2012 | name in title: PROSTVAC |
| PMID 23236591 | [The treatment of castration-resistant prostate cancer]. | Magyar onkologia | 2012 | name in abstract: PROSTVAC-VF |
| PMID 21106727 | Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2011 | name in abstract: PSA-TRICOM |
| PMID 21311328 | Novel agents and new therapeutics in castration-resistant prostate cancer. | Current opinion in oncology | 2011 | name in abstract: PROSTVAC |
| PMID 21675925 | Recent advances in immunotherapy for the treatment of prostate cancer. | Expert opinion on biological therapy | 2011 | name in abstract: PROSTVAC-VF/TRICOM |
| PMID 21700764 | Prostate cancer immunotherapy. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2011 | name in abstract: PROSTVAC-VF |
| PMID 21741424 | Immunotherapy in prostate cancer: emerging strategies against a formidable foe. | Vaccine | 2011 | name in abstract: PSA-TRICOM |
| PMID 21825260 | Immunotherapy for prostate cancer: biology and therapeutic approaches. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2011 | name in abstract: PROSTVAC-VF |
| PMID 20140811 | A year of successful cancer vaccines points to a path forward. | Current opinion in molecular therapeutics | 2010 | name in abstract: PROSTVAC-VF/TRICOM |
| PMID 20140819 | Therapeutic vaccines for prostate cancer. | Current opinion in molecular therapeutics | 2010 | name in abstract: PROSTVAC-VF/TRICOM |
| PMID 20179598 | Current status of immunological therapies for prostate cancer. | Current opinion in urology | 2010 | name in abstract: PROSTVAC |
| PMID 20209643 | Androgen ablation augments human HLA2.1-restricted T cell responses to PSA self-antigen in transgenic mice. | The Prostate | 2010 | name in abstract: PROSTVAC |
| PMID 21208850 | The current and emerging role of immunotherapy in prostate cancer. | Clinical genitourinary cancer | 2010 | name in abstract: PROSTVAC |
| PMID 19548854 | Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer. | Expert opinion on investigational drugs | 2009 | name in title: PROSTVAC-VF |
| PMID 18985183 | Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology | 2008 | name in abstract: rV-PSA-TRICOM |
| PMID 17458173 | Drug evaluation: Therion's rV-PSA-TRICOM + rF-PSA-TRICOM prime-boost prostate cancer vaccine. | Current opinion in molecular therapeutics | 2007 | name in title: rV-PSA-TRICOM |
| PMID 16390546 | A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer. | Journal of translational medicine | 2006 | name in title: PROSTVAC-VF |
| PMID 17084174 | Management of high risk metastatic prostate cancer: the case for novel therapies. | The Journal of urology | 2006 | name in abstract: PROSTVAC-VF |
| PMID 15945343 | Recent progress in management of advanced prostate cancer. | Oncology (Williston Park, N.Y.) | 2005 | name in abstract: PROSTVAC |
| PMID 16179960 | Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology | 2005 | name in abstract: PROSTVAC-VF |
| PMID 12435056 | Technology evaluation: PROSTVAC, Therion. | Current opinion in molecular therapeutics | 2002 | name in title: PROSTVAC |
| PMID 9933036 | Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer. | Urology | 1999 | name in title: PROSTVAC |
NIH grants
| Project | Title | Organisation | PI | Years | Linked by |
|---|---|---|---|---|---|
| ZIABC010598 | Human Immune Responses to Tumor Antigens for Cancer Immunotherapy | DIVISION OF BASIC SCIENCES - NCI | SCHLOM, JEFFREY | 2012–2025 | name in abstract: PSA-TRICOM |
| ZIABC010666 | Cancer Immunotherapy | DIVISION OF BASIC SCIENCES - NCI | GULLEY, JAMES L. | 2009–2025 | name in abstract: PROSTVAC-VF |
| ZICBC010981 | Biomarker Investigations for Clinical Trials | DIVISION OF BASIC SCIENCES - NCI | HESELMEYER, KERSTIN | 2025–2025 | name in abstract: PROSTVAC |
| ZICBC012029 | Tumor Immune MicroEnvironment Facility (Scientific Core) | DIVISION OF BASIC SCIENCES - NCI | LASSOUED, WIEM | 2021–2025 | name in abstract: PROSTVAC |
| ZIABC010944 | Strategies for Cancer Immunotherapy Development: Preclinical Studies | DIVISION OF BASIC SCIENCES - NCI | SCHLOM, JEFFREY | 2011–2024 | name in abstract: PSA-TRICOM |
| ZIABC010425 | Strategies for Cancer Immunotherapy Clinical Trials | DIVISION OF BASIC SCIENCES - NCI | SCHLOM, JEFFREY | 2009–2023 | name in abstract: rV-PSA-TRICOM |
| ZIABC011055 | Serum Antibody Profiling with a Carbohydrate Microarray | DIVISION OF BASIC SCIENCES - NCI | GILDERSLEEVE, JEFFREY | 2009–2023 | name in abstract: PROSTVAC-VF |
| ZIABC011896 | Evaluation of novel treatments in biochemically recurrent prostate | DIVISION OF BASIC SCIENCES - NCI | MADAN, RAVI | 2019–2023 | name in abstract: PSA-TRICOM |
| ZIABC010945 | Clinical trials employing cancer vaccine combination therapies | DIVISION OF BASIC SCIENCES - NCI | GULLEY, JAMES L. | 2009–2022 | name in abstract: PSA-TRICOM |
| ZIABC011547 | Cancer Immunotherapy Clinical Trials | DIVISION OF BASIC SCIENCES - NCI | STRAUSS, JULIUS | 2014–2022 | name in abstract: rF-PSA-TRICOM |
| ZIABC011897 | Evaluation of Immune-based Combinations in Metastatic Prostate Cancer | DIVISION OF BASIC SCIENCES - NCI | MADAN, RAVI | 2019–2021 | name in abstract: PROSTVAC |
| ZIABC012060 | Novel Anti-androgen strategies in Prostate Cancer | DIVISION OF BASIC SCIENCES - NCI | MADAN, RAVI | 2021–2021 | name in abstract: PROSTVAC |
| 26120120003 | PHASE II, RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF PROSTVAC (PSA-TRICOM) IN PATIENTS... (PROTOCOL UAZ2012-03-01). CONTRACTOR: UNIVERSITY OF ARIZONA. CONTRACT: HHSN261201200031I. PERIOD: 9 | UNIVERSITY OF ARIZONA | CHOW, SHERY | 2014–2020 | name in title: PSA-TRICOM |
| ZIASC010098 | The Evaluation of Novel Therapeutics for Genitourinary Malignancies | DIVISION OF CLINICAL SCIENCES - NCI | DAHUT, WILLIAM L. | 2009–2020 | name in abstract: rF-PSA-TRICOM |
| U01CA202939 | Developing clinical, immunologic and radiographic tools to measure the clinical effect of immunotherapy in biochemically recurrent prostate cancer | SLOAN-KETTERING INST CAN RESEARCH | KANTOFF, PHILIP W | 2016–2018 | name in abstract: PROSTVAC |
| U54MD010706 | Sociobiological Responses to Stress in Prostate Cancer Survivors | MEDICAL UNIVERSITY OF SOUTH CAROLINA | HUGHES-HALBERT, CHANITA A. | 2016–2016 | name in abstract: PROSTVAC |
| ZIABC010972 | Identification of human tumor-associated antigens | DIVISION OF BASIC SCIENCES - NCI | TSANG, KWONG YOK | 2009–2016 | name in abstract: rV-PSA-TRICOM |
| ZIABC010973 | Analyses of human T regulatory cells | DIVISION OF BASIC SCIENCES - NCI | TSANG, KWONG YOK | 2009–2016 | name in abstract: rV-PSA-TRICOM |
| ZIABC011281 | Combination therapies involving novel cancer vaccines | DIVISION OF BASIC SCIENCES - NCI | MADAN, RAVI | 2010–2013 | name in abstract: PROSTVAC-VF |
| ZIABC011280 | Cancer Therapy Trials using novel vaccine platforms | DIVISION OF BASIC SCIENCES - NCI | MADAN, RAVI | 2010–2012 | name in abstract: PROSTVAC-VF |
| Z01BC010666 | Cancer Therapy Clinical Trials Using Novel Recombinant Vaccines | DIVISION OF BASIC SCIENCES - NCI | GULLEY, JAMES L. | 2006–2008 | name in abstract: rF-PSA-TRICOM |
| Z01SC010098 | The Evaluation of Novel Therapeutics for Genitourinary Malignancies | DIVISION OF CLINICAL SCIENCES - NCI | DAHUT, WILLIAM L. | 2008–2008 | name in abstract: PSA-TRICOM |
| Z01BC010662 | Vaccine Clinical Trials | DIVISION OF BASIC SCIENCES - NCI | ARLEN, PHILIP M | 2006–2007 | name in abstract: rV-PSA-TRICOM |
| M01RR000056 | PH II RNDM DBL BLIND CONTRL'D STDY EVAL SFTY AND EFFICACY PROSTVAC-VF/TRICOM | UNIVERSITY OF PITTSBURGH AT PITTSBURGH | CHATTA, GURKAMAL S | 2005–2005 | name in title: PROSTVAC-VF/TRICOM |
| M01RR000042 | RECOMBINANT VACCINIA/PSA VACCINE IN PATIENTS WITH RECURRENCE OF PROSTATE CANCER | UNIVERSITY OF MICHIGAN AT ANN ARBOR | SANDA, MARTIN G | 1999–1999 | name in abstract: PROSTVAC |
Notes
PROSTVAC: vaccinia-PSA-TRICOM prime (rilimogene galvacirepvec, NCIt C38681, UNII 59WJ3TGA5K) followed by fowlpox-PSA-TRICOM boosts (rilimogene glafolivec, NCIt C29560, UNII 7PLH7RM47T); recorded as one program because it is one prime-boost product with a single combined INN pair and NCIt concept (C132990). unii left empty because the product has two. Phase 3 PROSPECT (1,297 men, mCRPC) stopped for futility at interim analysis, reported September 2017. PSA is KLK3; TRICOM = CD80 (B7.1), ICAM1, CD58 (LFA-3).
How to cite
rilimogene galvacirepvec/rilimogene glafolivec (AXP000178.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000178.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.